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THE POTENTIAL FOR BIAS IN PRINCIPAL CAUSAL EFFECT
ESTIMATION WHEN TREATMENT RECEIVED DEPENDS
ON A KEY COVARIATE1
By Corwin M. Zigler and Thomas R. Belin
Harvard University and University of California, Los Angeles
Motivated by a potential-outcomes perspective, the idea of prin-
cipal stratification has been widely recognized for its relevance in
settings susceptible to posttreatment selection bias such as random-
ized clinical trials where treatment received can differ from treat-
ment assigned. In one such setting, we address subtleties involved
in inference for causal effects when using a key covariate to predict
membership in latent principal strata. We show that when treatment
received can differ from treatment assigned in both study arms, in-
corporating a stratum-predictive covariate can make estimates of the
“complier average causal effect” (CACE) derive from observations in
the two treatment arms with different covariate distributions. Adopt-
ing a Bayesian perspective and using Markov chain Monte Carlo for
computation, we develop posterior checks that characterize the extent
to which incorporating the pretreatment covariate endangers estima-
tion of the CACE. We apply the method to analyze a clinical trial
comparing two treatments for jaw fractures in which the study proto-
col allowed surgeons to overrule both possible randomized treatment
assignments based on their clinical judgment and the data contained
a key covariate (injury severity) predictive of treatment received.
1. Introduction. All-or-none treatment noncompliance in the context of
a randomized two-arm clinical trial is perhaps the simplest and most com-
mon example in health-sciences research of potential confounding by a post-
treatment variable. One strategy to address confounding of treatment re-
ceipt with individual characteristics is the use of an instrumental-variable
method [McClellan, McNeil and Newhouse (1994)] which has been linked to
a potential-outcomes perspective on causal inference [Angrist, Imbens and
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Rubin (1996); Imbens and Rubin (1997); Frangakis and Rubin (1999)]. More
recently, strategies for addressing potential confounding by posttreatment
variables have been formalized using the framework of principal stratification
[Frangakis and Rubin (2002)], a central challenge of which is the classifica-
tion of patients into latent subclasses, called principal strata, that facilitate
causal treatment comparisons.
In the context of treatment noncompliance, the target for inference is of-
ten the “complier average causal effect (CACE)” [Imbens and Rubin (1997)],
which compares treatment outcomes with control outcomes in the principal
stratum of “compliers” who would potentially receive whichever treatment
is randomly assigned (as distinct from other principal strata where patients
may always receive a particular treatment). Such comparisons within princi-
pal strata are known as “principal effects” and permit causal interpretation.
Knowledge of membership in the stratum of compliers or in any other princi-
pal stratum requires knowledge of patients’ potential treatment receipts un-
der both possible randomized assignments, but this information will never
be observed in total for any individual in the population since treatment
received is only observed for the actually assigned treatment.
A battery of now-standard assumptions underlie methods for identifying
and estimating the CACE in settings framed as treatment noncompliance
[Angrist, Imbens and Rubin (1996)], but more recent attention [e.g., Hirano
et al. (2000); Jo and Stuart (2009)] has been paid to the use of pretreatment
covariates to increase precision or relax exclusion restrictions. One line of re-
search focuses on settings where patients randomized to the control arm do
not have access to the active treatment, that is, settings where the entire pop-
ulation would receive control if so assigned. The key feature of these settings
is that they allow patients who are assigned and receive active treatment
to be identified as compliers, which further allows pretreatment covariates
associated with membership in this stratum to be used in identifying which
patients randomized to control are exchangeable with compliers. Specifically,
these settings motivate so-called “two-stage” approaches that first use pre-
treatment covariates to estimate propensity scores [Rosenbaum and Rubin
(1983)] of membership in the complier stratum, then estimate outcomes con-
ditional on these so-called “principal scores” [Follmann (2000); Hill, Brooks-
Gunn and Waldfogel (2003); Joffe, Ten Have and Brensinger (2003); Joffe,
Small and Hsu (2007); Jo and Stuart (2009)]. Although some previous re-
search has framed the one-sided access to treatment as a nonessential detail
that merely simplifies exposition, we aim to illuminate that added complex-
ity can arise in more general settings where noncompliance exists in both
treatment arms.
When treatment received can deviate from treatment assigned in both
study arms, the use of pretreatment covariates to aid estimation of the
CACE is more complicated because no patient is known to belong to the
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stratum of compliers, precluding estimation of a model such as a propensity
score model for membership in the complier stratum. Joint-estimation meth-
ods that simultaneously model stratum membership and outcomes have been
employed in these settings [Hirano et al. (2000); Frangakis, Rubin and Zhou
(2002); Barnard et al. (2003); Griffin, McCaffrey and Morral (2008); Roy,
Hogan and Marcus (2008); Gallop et al. (2009)], which typically consist of
two underlying strata in addition to the compliers: “never-takers” who would
never receive the active treatment, and “always-takers” who would always
receive the active treatment. Through use of standard assumptions that will
be elaborated later, stratum membership for patients who receive a treat-
ment different from that assigned can be regarded as having been revealed,
with such individuals being either never-takers or always-takers, and covari-
ates associated with membership in these two “noncomplier” strata can be
identified. However, membership in the complier stratum is never directly
observed because patients who receive the assigned treatment (and thus
might be compliers) generally represent mixtures of compliers and never-
takers (in the control arm) or compliers and always-takers (in the treatment
arm). Since pretreatment covariates can only provide direct information
about characteristics of noncompliers, the role of such covariates in esti-
mating the CACE is to model which patients in the complier/noncomplier
mixtures are noncompliers, thus indirectly estimating the remaining portion
of the mixture to belong to the stratum of compliers.
In this article we employ a joint-estimation method using a Gibbs sam-
pling computational approach [Geman and Geman (1984); Gelfand and
Smith (1990)] in a setting where noncompliance exists in both randomization
arms. We aim to improve the estimate of the CACE through incorporation of
a compliance-predictive model that uses a key covariate to select compliers
from the complier/noncomplier mixtures. Our novel contribution is a de-
tailed exposition of scenarios in which observed data predict membership in
the noncomplier strata in a way that can select compliers in each treatment
group from different portions of the covariate distribution, potentially im-
plying that the estimated CACE is biased for the causal effect of treatment.
After introducing the motivating oral-surgery application in Section 2, Sec-
tion 3 formally defines a potential-outcomes inference framework and the
assumptions necessary for estimation of the CACE. Section 4 develops the
compliance-predictive model and corresponding estimation procedure. Sec-
tion 5 uses simulated examples to illustrate some posterior checks and illumi-
nate the potential for bias resulting from the compliance-predictive model,
and Section 6 illustrates the impact of using the key covariate to predict
compliance status in the oral-surgery setting. We conclude with a discus-
sion.
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2. Motivating oral-surgery clinical trial. Our motivating example con-
sists of 142 patients who were randomly assigned to receive treatment for
jaw fractures in the form of Maxillomandibular Fixation (MMF, control) or
Rigid Internal Fixation (RIF, active treatment). The study aimed to investi-
gate the putative advantages of the increasingly-popular RIF over the more
traditional MMF in a patient population thought to be prone to postoper-
ative complications. A degree of clinical flexibility was deemed essential to
the protocol, allowing treatment decisions to depart from the randomized
treatment assignment if deemed necessary by the treating surgeon. This
clinical latitude gives rise to possible concerns that more severely injured
patients were disproportionately selected into the more aggressive treatment
arm, as it is well accepted in the surgical community that the MMF pro-
cedure, which is less expensive, is appropriate for less severe injuries while
the RIF procedure, which is more resource-intensive, is appropriate for more
severe injuries. Although the exact rationale for treatment decisions was not
recorded, a continuously-scaled measure of injury severity (SEV ) was cal-
culated for each patient. This severity measure, originally developed as the
Mandible Injury Severity Score (MISS) [Shetty et al. (2007)], ranges from 0
(less severe) to 25 (extremely severe), and derives from anatomic and clini-
cal characteristics of the constituent jaw fractures. The outcome of interest
was a continuously-scaled General Oral Health Assessment Index (GOHAI )
[Atchison (1997)] measured at six months post-treatment, with higher values
suggesting better oral-health quality of life. In the face of “noncompliance”
(i.e., surgical judgment overriding the treatment assigned through the ran-
domization protocol), one could conduct intention-to-treat and as-treated
analyses [Shetty et al. (2008)], but the former addresses a question that
is arguably not the only scientific question of interest, the latter can give
rise to bias in estimates of the treatment effect, and neither accounts for
the plausible effect that subjective treatment decisions had on the analy-
sis.
3. Potential outcomes, principal strata and causal estimand. Definition
of principal strata and causal estimands requires development of a potential-
outcomes framework, often called the Rubin Causal Model [Rubin (1978a);
Holland (1986)]. Following previous development in the setting of all-or-
none treatment noncompliance in a two-arm clinical trial [Angrist, Imbens
and Rubin (1996)], we define potential outcomes and delineate the prin-
cipal strata that arise in our motivating setting. We then outline the as-
sumptions necessary for identifiability of the causal estimand of interest,
the CACE.
3.1. Potential outcomes and principal strata. First, we define the rele-
vant potential outcomes inherent in this clinical trial. Define Z as the vec-
tor of random treatment assignments for all patients in the study, with
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ith element Zi equal to 0 for assignment to MMF and 1 for assignment
to RIF. Let D(Z) be a vector with ith element Di(Z) denoting the ith
patient’s received treatment under assignment Z. Patients with Di(Z) = 0
would receive treatment with MMF under assignment Z, while patients with
Di(Z) = 1 would receive treatment with RIF under assignment Z. Further-
more, we use Yi(Z,D) to denote a patient’s potential GOHAI with respect
to Z and D. We adopt the stable unit treatment value assumption (SUTVA)
[Rubin (1978a)] here to indicate no interference between patients, allowing
us to write Di(Z) =Di(Zi) and Yi(Z,D) = Yi(Zi).
Principal strata in this setting are defined by all four possible values
of the pair (Di(0),Di(1)). We call the principal stratum of patients with
(Di(0) = 0,Di(1) = 1) “compliers” who will receive the assigned treatment
regardless of which treatment is assigned, and denote these patients as hav-
ing Si = c. Similarly, we can call the stratum with (Di(0) = 0,Di(1) = 0)
“never-takers” who will never receive treatment with RIF, denoting these
patients with Si = n, and the stratum of patients with (Di(0) = 1,Di(1) = 1)
“always-takers” who will always receive treatment with RIF, which we label
with Si = a. Finally, we define the principal stratum of “defiers” as those
with (Di(0) = 1,Di(1) = 0), or those who will always receive the treatment
opposite of that assigned, with Si = d.
Naturally, we observe only one component of (Di(0),Di(1)) and only one
component of (Yi(0), Yi(1)). To draw out this distinction between observed
and missing components, we write (Dobsi ,D
mis
i ) and (Y
obs
i , Y
mis
i ), where the
superscripts obs and mis denote the observed and missing potential out-
comes, respectively.
3.2. Assumptions for identifiability of causal estimands. As no complete
pair of potential outcomes is observable, we require additional assumptions
for identifiability of causal estimands. In addition to SUTVA, we adopt
a monotonicity assumption [Imbens and Angrist (1994)] disallowing the ex-
istence of the principal stratum of defiers, that is, there are no patients
who would receive MMF if assigned RIF but receive RIF if assigned MMF.
This setting with noncompliance resulting from clinicians’ judgment is un-
likely to produce a violation of the monotonicity assumption. The usefulness
of monotonicity lies in its implication that patients with Dobsi =Di(0) = 1
must belong to the stratum of always-takers and those withDobsi =Di(1) = 0
must belong to the stratum of never-takers. Stratum membership for those
who received the assigned treatment remains unidentified, as patients with
Dobsi =Di(0) = 0 represent a mixture of compliers and never-takers, while
those with Dobsi =Di(1) = 1 represent a mixture of compliers and always-
takers. The first three columns of Table 1 provide a summary of the possi-
ble principal strata for patients with each possible observed pattern of Zi
and Dobsi .
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Table 1
Possible principal strata for observed treatment assignment and receipt patterns and
summary statistics for SEV and GOHAI in the motivating oral-surgery setting
Treatment Treatment Possible principal strata Mean (SD) Mean (SD)
assigned, Zi received, D
obs
i (Zi) (Di(0),Di(1)) n SEV GOHAI
0 0 compliers or never-takers 53 12.8 (2.7) 42.8 (12.1)
(Di(0) = 0,Di(1) = 0 or 1)
0 1 always-takers 9 14.0 (2.0) 42.8 (11.9)
(Di(0) = 1,Di(1) = 1)
1 1 compliers or always-takers 40 13.2 (2.3) 44.5 (12.1)
(Di(0) = 1 or 0,Di(1) = 1)
1 0 never-takers 40 12.2 (3.0) 41.7 (9.3)
(Di(0) = 0,Di(1) = 0)
Inference for causal effects in clinical trials with treatment noncompliance
typically relies on another assumption, known as the exclusion restriction
[Angrist, Imbens and Rubin (1996)], stating that any effect of treatment
assignment, Z, on the outcome, Y , must be via an effect of treatment recei-
ved, D. After accounting for received treatment, random assignment no
longer affects GOHAI , or (Y (z)|Z = z,D(z) = d) = (Y (z)|D(z) = d) for z =
0,1 and d= 0,1.
With the above development, we define the CACE as the expected differ-
ence in potential GOHAI outcomes within the stratum of compliers:
CACE =E[Yi(1)− Yi(0)|Si = c].
4. Bayesian models for the CACE with the compliance-predictive feature.
We formulate our inference strategy with a phenomenological Bayesian model
following Imbens and Rubin (1997). The model is phenomenological in the
sense described by Rubin (1978a, 1978b), where the inference builds on po-
tentially observable quantities even though not all of the quantities will be
observed. The relevant random variables for each patient are Zi,Di(0),Di(1),
Yi(0), Yi(1) and Xi, where Xi denotes the ith patient’s SEV . We consider
these random variables realizations from a joint distribution, with Xi, Zi,
Dobsi and Y
obs
i observed for each patient. Our goal is to model the condi-
tional distributions of Yi(z) conditional on principal stratum, which requires
integration over missing values as a result of the unidentifiable mixtures over
the latent Si. This motivates a Gibbs-sampling strategy that first samples
the missing Si, thereby allowing assessment of the distributions of Yi(z)
conditional on the “complete compliance data” consisting of subpopulations
without mixture components.
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4.1. Structure of Bayesian inference. The joint distribution of the data
can be factored as follows:
f(Z, (Y(0),Y(1)), (D(0),D(1)),X) = f(Z,Y,S,X)
= f(Y,S,X|Z)f(Z)(4.1)
= f(Y,S,X)f(Z),
where the last equality holds due to randomization in the study design. We
facilitate Bayesian inference by writing the joint distribution of Y,S and X
as the product of independently identically distributed random variables
conditional on a generic parameter θ [de Finetti (1974)], where we denote
the prior distribution of θ as p(θ) and the posterior distribution of θ as
p(θ|Yobs ,Dobs ,X,Z)
(4.2)
∝ p(θ)
∫∫ ∏
f(Y obsi , Y
mis
i ,D
obs
i ,D
mis
i ,Xi|θ)dY
mis
i dD
mis
i .
As pointed out in Frangakis, Rubin and Zhou (2002) and Jin and Rubin
(2008), required integration over Dmis proves computationally difficult in
general, but as a result of randomization Ymis can be handled with standard
randomization-based tools. Furthermore, the difficult integration over Dmis
leads us to consider the joint posterior of (θ,Dmis),
p(θ,Dmis |Dobs ,Yobs ,X,Z)∝ p(θ)
∏
f(Dobsi ,D
mis
i , Y
obs
i ,Xi|θ),(4.3)
which is proportional to a standard posterior distribution of θ had Dmis
been observed [Jin and Rubin (2008)], further motivating the strategy of
first drawing Dmis and then sampling from the posterior distribution of θ
conditional on complete compliance data. Posterior distributions of the rele-
vant quantities follow from specification of both p(θ) and the models defined
in Section 4.2. We describe our prior distributions for θ in Section 4.4.
4.2. Models for principal strata and outcomes. To estimate the CACE,
we further factor the joint distribution in (4.1) as f(Y|S,X)f(S|X)f(X)f(Z),
and specify models for f(Y|S,X) and f(S|X). As the population consists
of three underlying strata, we follow the approach used in Frangakis, Rubin
and Zhou (2002) and Barnard et al. (2003), whereby we model f(S|X) with
two linked probit models, the first modeling membership in the never-taker
stratum and the second modeling membership in the complier stratum con-
ditional on exclusion from the never-taker stratum. We parameterize these
models as
Ψn(Xi, β) = P (Si = n|Xi, β) = 1−Φ(β00 + β01Xi),
Ψc(Xi, β) = P (Si = c|Xi, β)
(4.4)
= {1−Ψn(Xi, β)}{1−Φ(β10 + β11Xi)} and
Ψa(Xi, β) = P (Si = a|Xi, β) = 1−Ψn(Xi, β)−Ψc(Xi, β),
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where β = (β00, β01, β10, β11) and Φ is the standard normal cumulative dis-
tribution function. To facilitate computation, we represent these models as
arising from underlying continuous random variables Sni and S
c
i ,
Si = n if S
n
i = β00 + β01Xi + Vi ≤ 0,
Si = c if S
n
i > 0 and S
c
i = β10 + β11Xi +Ui ≤ 0 and(4.5)
Si = a if S
n
i > 0 and S
c
i > 0,
where the Vi and Ui are independently distributed as N(0,1).
We illustrate the analysis with two different models for f(Y|S,X). The
first model (Model A) entails a regression adjustment for the key covariate’s
association with the outcome:
f(Yi(z)|Xi, Si = n) = gn(Yi|α
n
0 , α
n
1 ,Xi, σ
2)∼N(αn0 + α
n
1Xi, σ
2),
f(Yi(z)|Xi, Si = a) = ga(Yi|α
a
0 , α
a
1,Xi, σ
2)∼N(αa0 +α
a
1Xi, σ
2) and
(4.6)
f(Yi(z)|Xi, Si = c,Zi = z)
= gcz(Yi|α
cz
0 , α
cz
1 ,Xi, σ
2)∼N(αcz0 + α
cz
1 Xi, σ
2) for z = 0,1,
implying the exclusion restriction and the assumption that GOHAI out-
comes are distributed with the same variance in each stratum and for each
treatment receipt. For comparison purposes, we also conduct the analysis
under another model (Model B) that does not explicitly incorporate X in
the model for Y (z), entailing the additional assumption that Y (z) ⊥ X|S.
That is, Model B incorporates the restriction that αn1 = α
a
1 = α
c0
1 = α
c1
1 = 0,
representing a “standard” unadjusted CACE analysis.
The observed-data likelihood reflecting the mixtures over the latent Si
can be written as
Lobs(θ|Z,D
obs ,Yobs ,X)
=
∏
Zi=1,Dobsi =0
{Ψn(Xi, β) · gn(Yi|α
n
0 , α
n
1 ,Xi, σ
2)}
×
∏
Zi=0,Dobsi =1
{Ψa(Xi, β) · ga(Yi|α
a
0, α
a
1,Xi, σ
2)}
×
∏
Zi=0,Dobsi =0
{Ψn(Xi, β) · gn(Yi|α
n
0 , α
n
1 ,Xi, σ
2)(4.7)
+Ψc(Xi, β) · gc0(Yi|α
c0
0 , α
c0
1 ,Xi, σ
2)}
×
∏
Zi=1,Dobsi =1
{Ψa(Xi, β) · ga(Yi|α
a
0, α
a
1,Xi, σ
2)
+Ψc(Xi, β) · gc1(Yi|α
c1
0 , α
c1
1 ,Xi, σ
2)},
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where θ = (β00, β01, β10, β11, α
n
0 , α
n
1 , α
a
0, α
a
1, α
c0
0 , α
c0
1 , α
c1
0 , α
c1
1 , σ
2) and the prod-
uct over Zi = z,D
obs
i = d represents the product over all patients assigned
treatment z who were observed to receive treatment d.
As a result of random assignment to treatment, the Y misi in the stratum of
compliers is sampled from the distribution gc(1−Zi) and the CACE estimate
is calculated as
CACE =E[Yi(1)− Yi(0)|Xi, Si = c] =
1
nc
∑
Si=c
(Yi(1)− Yi(0)),
where nc is the number of patients with Si = c at the current iteration.
4.3. Sampling compliers within the compliance-predictive model. Despite
the existence of three underlying strata, the step of the Gibbs sampler that
determines patients’ unknown compliance status does so via Bernoulli distri-
butions reflecting the fact that patients who received the assigned treatment
can belong to one of only two possible strata. Owing to these underlying two-
component mixtures, the probability at a given iteration of the sampler that
a patient with Zi =D
obs
i = z belongs to stratum of compliers is
P (Si = c|Xi, Y
obs
i ,D
obs
i ,Zi, θ)
= Ψc(Xi, β) · gcz(Yi|α
cz
0 , α
cz
1 ,Xi, σ
2)
(4.8)
/(Ψc(Xi, β) · gcz(Yi|α
cz
0 , α
cz
1 ,Xi, σ
2)
+Ψt(Xi, β) · gt(Yi|α
t
0, α
t
1,Xi, σ
2)),
where t= n if z = 0 and t= a if z = 1. Examining these probabilities makes
clear that the relative impacts of Xi and Y
obs
i on (4.8) depend on the extent
to which X predicts stratum and on the amount of overlap between the
distributions gcz and gt.
4.4. Additional model specifications and statistical computing details. We
treat the elements of θ to be a priori independent, using conditionally-con-
jugate normal distributions for the β,αn0 , α
n
1 , α
a
0, α
a
1, α
cz
0 , α
cz
1 , and a conditio-
nally-conjugate gamma distribution for the precision parameter 1
σ2
. The dis-
tributions for (αn0 , α
a
0, α
cz
0 ) are centered at the overall sample mean GOHAI
with variances of 100, and the distributions for (αn1 , α
a
1, α
cz
1 ) are centered at 0
with variances of 100. The prior distribution for the precision parameter is
gamma with shape and scale parameter set to 0.01. Prior distributions for
the elements of β are centered at 0 with variance 5.
After a burn-in of 5,000 iterations, each chain is run for 5,000 additional
iterations, saving every 10th sample. For each model, three chains are run
from different starting values, and the potential scale-reduction statistics
[Gelman and Rubin (1992); Gelman et al. (2004)] are calculated for each
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parameter to assess convergence. All parameters in all models had potential
scale-reduction statistics less than or equal to 1.06, suggesting satisfactory
convergence. For each model, the three chains are combined to calculate
posterior estimates.
5. Illustration of the potential for Bias in the CACE using simulated
data. To illustrate that the compliance-predictive model can imply com-
plier treatment groups with different characteristics and to illustrate our
graphical diagnostic, we examine in detail a simulated scenario where X is
predictive of stratum membership and the true CACE = 0. Details of this
simulation and a broader simulation study appear in a supplementary web
appendix [Zigler and Belin (2011)].
To investigate the relationships between X and stratum membership un-
der Model A, we examine posterior-predictive distributions of the probabil-
ities in (4.8) for a hypothetical group of patients having an X distribution
mirroring that in the observed data. Figure 1(a) displays, for z = 0,1, his-
tograms of the observed X distributions in patients with Zi =D
obs
i = z, with
histogram bars shaded according to the mean posterior-predictive probabil-
ity of membership in the complier stratum for a value of X at that point of
Fig. 1. Results from simulated data sets where X predicts stratum membership. As the
procedure selects compliers from opposite ends of the severity distribution ( a), estimates
of the CACE can become particularly susceptible to model misspecification (b). Thick
lines in (b) are posterior means and thin lines are 95% posterior intervals. For each
value of Corr(X,Y ), posterior summaries are averaged over 50 Monte Carlo simulations.
All simulations have CACE = 0 (horizontal dotted line). ( a) Observed SEV distributions
shaded corresponding to P (Si = c|Xi, Y
obs
i ,D
obs
i ,Zi, θ). (b) Posterior CACE estimates un-
der Models A and B.
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the histogram and for Y obsi equal to the mean value observed in patients with
Zi =D
obs
i = z. Note the different shading patterns in the two histograms.
For Zi =D
obs
i = 0, histogram bars are darker as X increases (more severely
injured patients are more likely compliers), while for Zi = D
obs
i = 1, his-
togram bars are lighter as X increases (more severely injured patients are
less likely compliers). For example, note that patients with X in the range
[9,12] in the Zi = D
obs
i = 1 group have probability of membership in the
complier stratum near 1.0, while patients with the same range of SEV in
the Zi = D
obs
i = 0 group have probability of membership in the complier
stratum in the range [0.1− 0.4]. The implication for estimates of the CACE
is that over the course of the sampler, patients in the observed mixture of
compliers and always-takers (Zi =D
obs
i = 1) with lower X will more often
contribute to the CACE than patients with comparable X in the observed
mixture of compliers and never-takers (Zi =D
obs
i = 0). The opposite sam-
pling disparity holds for patients with higher X . If X is also related to the
primary outcome, Y , a situation such as that depicted in Figure 1(a) leaves
estimates of the CACE particularly vulnerable to misspecified models that
incorrectly extrapolate to areas of the X distribution where there is limited
data. For example, estimation of a typical unadjusted CACE (Model B)
would represent one such misspecified model, and could lead to vastly dif-
ferent estimates of the CACE. To illustrate this point, Figure 1(b) displays
posterior estimates of the CACE using both Model A and Model B in scenar-
ios where X is related to stratum membership and with varying magnitudes
of the relationship between X and Y . We see that under Model B, the im-
balanced sampling of compliers evident from Figure 1(a) leads to bias in the
estimated CACE that is increasing in |Corr(X,Y )|, providing misleading
results even when the association between X and Y is modest and in some
cases estimating a significant treatment effect when there in fact is none.
The same bias is not depicted under Model A because even though there is
limited data on comparable compliers in some areas of the X distribution,
extrapolation of Model A to these areas of the distribution correctly reflects
the underlying relationship; that is, there is no model misspecification. The
supplementary web appendix [Zigler and Belin (2011)] considers simulations
under a broader range of relationships between X and both stratum mem-
bership and Y and further indicates the potential for bias in the CACE
when using a compliance-predictive covariate.
6. Using SEV to predict principal strata in the motivating oral-surgery
study. As described in Table 1, patients in the oral-surgery example who
had assignment to MMF overruled (known always-takers) had higher aver-
age X than the rest of the sample, patients who had assignment to RIF
overruled (known never-takers) had lower average X than the rest of the
sample, and there was a relatively high estimated proportion of never-takers
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Fig. 2. Posterior-predicted probabilities of membership in the complier stratum for hy-
pothetical patients with Zi =D
obs
i = z in the oral-surgery study under Model A
∗, z = 0,1.
( a) Posterior mean (solid) and 95% intervals (dashed) for P (Si = c|Xi, Y
obs
i ,D
obs
i ,Zi, θ).
(b) Observed SEV distributions shaded corresponding to P (Si = c|Xi, Y
obs
i ,D
obs
i ,Zi, θ).
(50.0%) and a relatively low proportion of always-takers (14.5%). The oral-
surgery example had missing Y for a substantial proportion of the patients.
Based on observed data, the nonresponse rates were 48.4%, 46.2% in the
Z = 0,1 arms, respectively, and 55.6%, 45.0% in the observed always-takers,
never-takers, respectively. To prevent complication of our illustrative goal,
we assume in the models for the oral-surgery data that (1) the Si are inde-
pendent of the missing indicator and (2) the missing Y are latently ignorable
conditional on Si and Zi [Frangakis and Rubin (1999)]. The implication of
these assumptions for the computation is that missing Y are drawn at each
iteration from the distribution for patients’ current stratum membership
conditional on current values of the parameters. Furthermore, the small
number of observed Y values precludes useful estimation of all of the α pa-
rameters in (4.6), leading us to alter Model A to Model A∗ that includes the
constraint that αn1 = α
a
1 = α
c0
1 = α
c1
1 .
The observed relationship between X and membership in the never-taker
and always-taker strata (Table 1) prompts examination of the probabilities
of selection into the stratum of compliers within the compliance-predictive
model. Figure 2(a) shows the posterior predictive distributions of the Ber-
noulli probabilities in (4.8) for hypothetical patients with Y equal to the
observed sample mean, X across the range observed in the data, and Zi =
Dobsi = z for z = 0,1. The unequal proportions of underlying strata are re-
flected in this figure by the fact that the probability of being sampled as
a complier is consistently higher for the patients with Zi =D
obs
i = 1 than
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for those in the other treatment arm; the low estimated proportion of always-
takers (9/62 = 0.14) implies that most patients with Zi =D
obs
i = 1 belong
to the stratum of compliers.
The wide spread of the posterior predictive distributions in Figure 2(a)
suggests that X has limited utility for identifying which patients are com-
pliers, but there is some indication that the relationship between X and the
probability of membership in the complier stratum is slightly different at
the high end of the X distribution depending on the value of Zi and D
obs
i .
To assess the potential for these relationships to affect the sampling of com-
pliers, we examine in Figure 2(b) the posterior-predictive probabilities of
membership in the complier stratum for hypothetical patients with X dis-
tributions identical to those observed in the sample with Zi =D
obs
i = z and
with Y equal to the mean value observed in patients with Zi =D
obs
i = z,
for z = 0,1. This illustration provides limited evidence that patients with
different values of Zi and D
obs
i are sampled as compliers from different ar-
eas of their respective X distributions. There is a slight positive association
between X and membership in the complier stratum in the Zi =D
obs
i = 0
patients (evidenced by the darkening of the histogram bars as X increases)
that differs from the negative association in the Zi =D
obs
i = 1 patients (ev-
idenced by the lightening of the histogram bars as X increases), but the
amount of uncertainty in these posterior probabilities likely precludes any
serious effect on the estimated CACE.
Overall, the information in Figure 2 does not provide any strong indica-
tion that the compliance-predictive model estimates a CACE calculated from
compliers with different injury characteristics in the two treatment groups.
To explore the sensitivity to alternative models for stratum membership, we
adapt Model A∗ to replace the probit models in (4.4) with a multinomial
logit model along the lines of that used in Hirano et al. (2000), and refer to
this as Model C∗. Using Model C∗, figures analogous to Figure 2(a) and (b)
appear largely indistinguishable from those under Model A∗ and are not
pictured. Table 2 summarizes posterior CACE estimates from a compliance-
predictive analysis under Model A∗, Model B and Model C∗, as well as
Table 2
Posterior estimates of the CACE in the motivating oral-surgery study using a
model without the compliance-predictive covariate and using three
compliance-predictive strategies
Modeling strategy Posterior mean SD 2.5% 97.5%
Compliance-predictive Model A∗ 2.65 7.3 −8.9 20.9
Compliance-predictive Model B 0.17 7.0 −13.0 16.0
Compliance-predictive Model C∗ 1.95 6.7 −9.6 18.9
Model without SEV 0.74 6.4 −11.0 13.6
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from an analysis following Imbens and Rubin (1997) that does not explicitly
use the SEV covariate at all and places a noninformative conditionally-
conjugate Dirichlet prior distribution on the population proportions of prin-
cipal strata. None of these models provide evidence of a treatment effect,
and all three compliance-predictive models offer slightly decreased precision,
most likely due to the lack of information contained in the SEV covariate
regarding stratum membership and the inclusion of extraneous model pa-
rameters.
7. Discussion. Using covariates to model membership in latent principal
strata has many advantages in estimating the CACE. We provide a detailed
illustration of the subtlety involved in using a key covariate when noncom-
pliance exists in both treatment arms. In particular, we show that when
a covariate is related to stratum membership, a joint-estimation method
can imply treatment groups in the latent stratum of compliers with different
covariate characteristics. The resulting danger of comparing compliers with
different characteristics can be alleviated with modeling assumptions that
correctly extrapolate the treatment effect to areas of the covariate distri-
bution where compliers are not estimated to exist in both treatment arms.
However, this differential sampling of patients into the complier stratum
poses a serious threat to the CACE under model misspecification, includ-
ing calculation of the standard unadjusted CACE when a covariate predicts
stratum membership. We propose simple graphical posterior checks that in-
dicate the extent to which the estimated CACE relies on compliers that have
different covariate characteristics, potentially characterizing the danger for
model misspecification to bias the estimated CACE.
Our aim is not to discourage the use of covariates that are predictive of la-
tent stratum membership but rather to shed light on the subtleties involved
and to provide guidance on how to detect whether a compliance-predictive
model endangers estimates of the CACE. Our motivating oral-surgery ex-
ample is somewhat unique in its availability of a key covariate that was
thought to influence the treatment received, but the possibility of covariates
relating to stratum membership can arise elsewhere, as with the random-
ized encouragement design considered in Hirano et al. (2000) where age and
presence of chronic obstructive pulmonary disease (COPD) were thought to
influence whether patients were in the underlying stratum of individuals who
would always receive a flu vaccination regardless of random encouragement
to do so. The authors of that work include compliance-predictive models
to relax exclusion restrictions and provide posterior estimates of model pa-
rameters suggestive of a different relationship between age and COPD and
the probability of membership in the complier stratum depending on the
values of Zi and D
obs
i . Whether their model tended to consider a complier
stratum consisting of younger patients without COPD in the Z = 1 arm and
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older patients with COPD in the Z = 0 arm could be assessed by examining
posterior probabilities of stratum membership across the observed ranges of
these covariates.
We present models that do and do not adjust the CACE for levels of the
key covariate. We frame the choice not to model Y conditional on both S
and X (as in Model B) as a form of model misspecification, but in real
applications researchers are confronted with the decision to calculate the fa-
miliar unadjusted CACE or to specify a more detailed model for f(Y|S,X)
and estimate an adjusted CACE. We show that when a covariate is used to
model stratum membership, estimation of the unadjusted CACE can pro-
duce biased results. Thus, we recommend that the CACE be adjusted for any
covariates used to model stratum membership, which is contrary to previous
recommendations that stratum-predictive covariates need not be included in
models for outcomes within strata [Gallop et al. (2009)]. Furthermore, spec-
ification of a more detailed model for f(Y|S,X) does not guarantee correct-
ness, and we provide a framework to assess whether model misspecification
poses a particular danger to estimation of a covariate-adjusted CACE that
can depend on areas of the covariate distribution where there is limited
data.
The core features of the scenario presented here, namely, that a complian-
ce-predictive model must respect the presence of three underlying strata
while a patient of unknown stratum can belong to one of only two strata, can
have conflicting impacts. One way to characterize these issues is to view mod-
eling membership in the complier stratum not as selection of compliers but
rather as a process for selection of “nonnoncompliers” from both treatment
arms since, no matter how predictive, the compliance-predictive feature is
anchored to observed information on always-takers and never-takers and
can only indirectly model membership in the stratum of primary interest.
Some applications focus on treatment effects within principal strata anal-
ogous to always-takers [Hudgens, Hoering and Self (2003); Gilbert, Bosch
and Hudgens (2003); Shepherd et al. (2006); Hudgens and Halloran (2006);
Roy, Hogan and Marcus (2008)] and are less susceptible to the type of bias
depicted here because, as in settings where noncompliance exists in only one
treatment arm, the data provide direct evidence on the relationship between
covariates and the stratum of primary interest.
We have characterized scenarios that lend themselves to the use of a com-
pliance-predictive covariate but leave an opening for bias in the estimation
of the CACE. Such scenarios warrant careful model checking; in Sections 5
and 6 we propose steps to investigate the potential for bias. Future research
on methods that use stratum-predictive covariates to estimate the CACE
when the data consist of three underlying strata would prove valuable in set-
tings where it is appealing to use covariates to aid identifiability or improve
precision of causal estimates.
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SUPPLEMENTARY MATERIAL
Simulation study (DOI: 10.1214/11-AOAS477SUPP; .pdf). A detailed ex-
position of the potential for bias using a richer set of simulations.
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